Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNPX GENPREX	$0.21 -1.8%	$0.26	$0.20 ▼ $3.97	$7.03M	-0.53	1.08 million shs	1.06 million shs
KZR Kezar Life Sciences	$3.97 -0.3%	$4.35	$3.62 ▼ $9.18	$29.07M	0.65	44,551 shs	42,565 shs
MDCX Medicus Pharma	$1.96 -1.0%	$2.74	$1.80 ▼ $8.94	$26.60M	N/A	332,164 shs	186,008 shs
MIRA MIRA Pharmaceuticals	$1.50 +2.0%	$1.42	$0.73 ▼ $2.70	$28.60M	1.77	561,375 shs	272,804 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNPX GENPREX	0.00%	-0.75%	-25.15%	-14.16%	-70.94%
KZR Kezar Life Sciences	0.00%	-1.00%	-10.99%	-2.46%	-34.86%
MDCX Medicus Pharma	0.00%	-0.51%	-39.69%	-70.88%	+195,999,900.00%
MIRA MIRA Pharmaceuticals	0.00%	+8.70%	-25.74%	+3.45%	-22.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNPX GENPREX	1.8147 of 5 stars	0.0	3.0	4.7	3.5	0.0	0.6
KZR Kezar Life Sciences	3.8402 of 5 stars	3.2	0.0	4.6	2.0	3.3	0.6
MDCX Medicus Pharma	1.9331 of 5 stars	3.8	0.0	0.0	1.5	1.7	0.0
MIRA MIRA Pharmaceuticals	3.2535 of 5 stars	3.8	5.0	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNPX GENPREX	0.00	N/A	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$9.00	126.70% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,098.98% Upside
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,033.33% Upside

Current Analyst Ratings Breakdown

Latest GNPX, KZR, MDCX, and MIRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.15 per share	N/A
KZR Kezar Life Sciences	$7M	4.15	N/A	N/A	$12.53 per share	0.32
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.24 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-724.98%	-369.33%	N/A
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	N/A
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.49	N/A	N/A	N/A	N/A	-329.63%	-271.22%	N/A

Latest GNPX, KZR, MDCX, and MIRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GNPX GENPREX	-$0.71	-$0.17	+$0.54	-$0.17	N/A	N/A
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNPX GENPREX	N/A	1.94	1.94
KZR Kezar Life Sciences	0.03	7.29	7.09
MDCX Medicus Pharma	N/A	1.29	1.53
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNPX GENPREX	14.05%
KZR Kezar Life Sciences	67.90%
MDCX Medicus Pharma	N/A
MIRA MIRA Pharmaceuticals	35.16%

Insider Ownership

Company	Insider Ownership
GNPX GENPREX	0.44%
KZR Kezar Life Sciences	10.40%
MDCX Medicus Pharma	11.20%
MIRA MIRA Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNPX GENPREX	20	33.15 million	33.00 million	No Data
KZR Kezar Life Sciences	60	7.32 million	6.56 million	Not Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable

GNPX, KZR, MDCX, and MIRA Headlines

Recent News About These Companies

MIRA Pharmaceuticals’ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus ...

August 14 at 11:19 AM | dispatch.com

MIRA Pharmaceuticals’ Ketamir-2 Shows Promising Preclinical Results

August 12, 2025 | msn.com

Mira announces acceptance of second Ketamir-2 manuscript for publication

August 12, 2025 | msn.com

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine ...

August 12, 2025 | finance.yahoo.com

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

August 12, 2025 | accessnewswire.comA

MIRA Pharmaceuticals (MIRA) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

MIRA Pharmaceuticals Announces Virtual Annual Meeting to Discuss SKNY Merger

August 9, 2025 | msn.com

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

July 30, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

July 29, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Gets FDA Clearance for Ketamir-2 Trials

July 28, 2025 | tipranks.com

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for ...

July 11, 2025 | sacbee.comS

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

July 11, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Reports Promising SKNY-1 Preclinical Results

July 10, 2025 | tipranks.com

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 10, 2025 | uk.finance.yahoo.com

Mira Pharmaceuticals raises $2 million through at-the-market stock sale

July 9, 2025 | investing.com

MIRA Pharmaceuticals Raises $2M Through Stock Sale

July 8, 2025 | tipranks.com

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

July 3, 2025 | accessnewswire.comA

MIRA Pharmaceuticals: MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving ... - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

MIRA Data Shows Improved Weight Loss Potential

July 1, 2025 | finance.yahoo.com

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive ...

June 30, 2025 | palmbeachpost.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, KZR, MDCX, and MIRA Company Descriptions

GENPREX NASDAQ:GNPX

$0.21 0.00 (-1.76%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$0.21 +0.00 (+0.85%)

As of 08/15/2025 07:45 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Kezar Life Sciences NASDAQ:KZR

$3.97 -0.01 (-0.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.09 +0.12 (+2.92%)

As of 08/15/2025 07:56 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Medicus Pharma NASDAQ:MDCX

$1.96 -0.02 (-1.01%)

As of 08/15/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.50 +0.03 (+2.04%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.02 (-1.33%)

As of 08/15/2025 07:59 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time